Trospium Chloride Tabs Rx
Generic Name and Formulations:
Trospium chloride 20mg; tabs.
Various generic manufacturers
Indications for Trospium Chloride Tabs:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Take on empty stomach. 20mg twice daily. ≥75yrs: 20mg once daily if twice daily dose not tolerated. Severe renal impairment (CrCl<30mL/min): 20mg once daily at bedtime.
Gastric or urinary retention; uncontrolled narrow-angle glaucoma; and patients at risk for these conditions.
Bladder outflow obstruction. GI obstructive disorders. Ulcerative colitis. Narrow-angle glaucoma (monitor). Intestinal atony. Myasthenia gravis. Exposure to high environmental temperature. Renal insufficiency (CrCl 30–80mL/min). Moderate to severe hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers.
Additive anticholinergic effects with other anticholinergics. Increased drowsiness with alcohol; avoid consumption within 2hrs of administration. May alter absorption of other drugs (decreased GI motility). May potentiate or be potentiated by drugs eliminated by active tubular secretion. May be antagonized by metformin.
Anticholinergic effects (dry mouth, constipation, dry eyes, urinary retention, blurred vision), CNS effects (monitor), dyspepsia, headache.
Formerly known under the brand name Sanctura, Sanctura XR.
Fecal (primarily), renal.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|